Biotechnology
Latest news, analysis, and insights from ASX biotechnology companies
Recce Pharmaceuticals Signs Distribution Agreement for R327 Diabetic Foot Gel across MENA
Recce inks 10-year exclusive MENA licensing deal for R327G diabetic foot gel; upfront fees up to $5m, 30% net sales, Phase III data eyed for year-end approval.
Latest Stories
EMVision Medical Devices De-Risks Rural Stroke Use Cases with Aeromedical Study
EMVision de-risks rural stroke use with aeromedical feasibility study; First Responder Brain Scanner unaffected by flight, cash reserves of $18.4m.
Noxopharm Studies Confirm Cancer-Fighting Potential of Sofra Platform
Noxopharm data show Sofra's TLR8-boosting oligonucleotides could amplify cancer immunotherapy; US patent backing strengthens breakthrough potential.
NeuroScientific Biopharmaceuticals Reports Positive Results from StemSmart Crohn’s Trial
NeuroScientific reports on StemSmart Crohn’s trial: 80% clinical response in five patients; safe, paving Phase 2 and a potential entry to a US$13.8B market.
Aroa Biosurgery Sets Ambitious FY27 Targets after Exceeding FY26 Guidance
Aroa Biosurgery beats FY26 guidance as Myriad drives revenue 23% YoY; FY27 targets NZ$115-125m, Symphony catalyst; cash-rich, debt-free.
IMEXHS Wins Major Public Tender in Mexico for Aquila+ Platform
IMEXHS wins Mexico tender for Aquila+ AI radiology, adding US$384k ARR and US$50k fee as 20 sites deploy by June 2026; FY25 profitability improves.
Vitrafy Life Sciences Reports Strong US Army Platelet Preservation Results
Vitrafy Life Sciences announces 94% post-thaw platelet recovery with 3% DMSO no-wash protocol, independent validation for frozen platelets.
TrivarX Engages Beyond Drug Development to Progress Stabl-Im Safety Trial
TrivarX engages Beyond Drug Development to push Stabl-Im Phase 1 safety trial, targeting H2 2026 start and data for regulatory progress.
AFT Pharmaceuticals Targets Minimum $300m Revenue After Record Earnings
AFT Pharmaceuticals targets over $300m revenue in FY27 after record FY26 earnings; Australasia core, expanding international hubs.
Nyrada Announces Preclinical Oncology Efficacy for Xolatryp and US Patent Allowance
Nyrada reports strong preclinical Xolatryp efficacy in liver cancer and a US patent allowance, highlighting a ~39% boost vs doxorubicin alone.
OncoSil Medical Secures TGA Approval in Australia for Pancreatic Cancer Device
OncoSil Medical wins TGA approval for OncoSil device to treat unresectable LAPC; ARTG-listed, enabling Australian launch as manufacturing scales up.
Mach7 Technologies Lands New US Customer AMRADNET on 5-Year Deal
Mach7 wins US AMRADNET deal worth A$1.7M, 5-year ARR; deployment cut to 45 days, signaling accelerated growth post-transformation.